H. S. Zackheim

The state-of-the art therapy of cutaneous T cell lymphoma (CTCL) is reviewed. Commonly used treatments for early-stage (patch/plaque) mycosis fungoides (MF) include topical corticosteroids, mechlorethamine, carmustine, ultraviolet light B and PUVA. Total skin electron beam (TSEB) therapy is indicated for widespread infiltrated plaque and tumor stage disease. Low-dose methotrexate is often useful for resistant patch/plaque MF and erythrodermic CTCL. Interferon alpha (IFN-alpha) is indicated for methotrexate failures and recurrent tumors following TSEB therapy. Photopheresis may be helpful for early-stage erythrodermic CTCL but is very costly. Retinoids may be of value for early and moderately advanced CTCL particularly in combination with other agents such as IFN-alpha and PUVA. Systemic disease usually requires combination chemotherapy such as that used for non-Hodgkin's lymphoma; however, responses are usually short lived.

Publications relating to cutaneous T-cell lymphomas (CTCLs) (principally mycosis fungoides and the Sézary syndrome), which appeared primarily from 1977 to 1979, are reviewed. A wide variety of topics, including pathogenesis, immunologic characteristics, lymphoid cell morphologic characteristics, cytogenetics, clinical reports, and topical, radiation, and other therapies, are included. Although CTCLs make up a relatively small part of the spectrum of cutaneous disease, the impressive body of literature speaks for a considerable interest in this group of potentially fatal disorders.

This article summarizes experience with topical carmustine (BCNU) solution in 172 patients with patch/plaque stage mycosis fungoides. At 36 months 92% of stage-T1 (less than 10% skin involvement) and 64% of stage-T2 (10% or more skin involvement) patients were either in complete or partial remission. The most frequent side effect was an erythematous reaction which was followed by a benign-type telangiectasia in some patients. No secondary skin cancers were seen. Bone marrow depression was uncommon. Topical BCNU is an effective treatment for patch/plaque stage mycosis fungoides.

Research Articles| June 03 2009 Comparative Cutaneous Carcinogenesis in the Rat: Differential Response to the Application of Anthramine, Methylcholanthrene, and Dimethylbenzanthracene Subject Area: Oncology H.S. Zackheim H.S. Zackheim From the Department of Dermatology, Wayne State University College of Medicine and the Detroit Institute of Cancer Research, Detroit, Michigan Search for other works by this author on: This Site PubMed Google Scholar Oncologia (1964) 17 (3-4): 236–246. https://doi.org/10.1159/000224234 Article history Published Online: June 03 2009 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation H.S. Zackheim; Comparative Cutaneous Carcinogenesis in the Rat: Differential Response to the Application of Anthramine, Methylcholanthrene, and Dimethylbenzanthracene. Oncologia 31 December 1964; 17 (3-4): 236–246. https://doi.org/10.1159/000224234 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsOncologia Search Advanced Search Article PDF first page preview Close Modal This content is only available via PDF. 1964Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.